In the News
November 19, 2025

Accelerating pharma innovation with Norstella and AWS

Our CEO, Kris Joshi, joined industry leaders at the second annual AWS Healthcare Investor and Executive Summit to discuss how technology and AI are shaping the future of healthcare and life sciences.

He highlights the challenge that critical data is often fragmented across many sources, and describes how Norstella integrates these datasets to make them easily accessible for AI-driven applications. This approach significantly reduces the time it takes for users to move from question to insight. Joshi emphasizes Norstella’s mission-driven focus on improving patient outcomes by accelerating therapy development, lowering costs, and ultimately making drugs more affordable through more efficient research and clinical processes.

Video transcript

Hello, I’m Chris Joshi, CEO of North Stella. I am, uh, pleased to be here today to talk a little bit about how North Stella is innovatingfor our customers in the biopharmaceutical industry and how we are partnering with AWS. Our customers are asking us for answersto their business and clinical questions to be delivered more quickly and with higher accuracy and reliability. Now, that is easier said than donebecause the data that drives these decisions is often spread out and fragmented across many, many different sources. What we do at North Stella is we bring allof these data sets together to put it in a form that makes it more easily accessible for AI driven applications on top.By doing that successfully, we’ve been able to reduce the time it takes for a customer, a business user, or a clinical user to go from askinga question to receiving an answer. We are a mission-driven company. We love solving problems for our customers, knowing that by doing that, we are doing good, uh, for every patient everywhere in the world, we wanna see the time it takes to bring new therapies to market should be shortened so that we can speed therapies to market faster at a lower cost. We wanna see drugs becoming more affordable because the clinical development and, and research become more efficient, and in the end give us a better, faster, cheaper therapies for everyone.